Tempus AI
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop an...
Latest News
4 days ago · newsfilecorp.com
Arizona Eagle Mining Corp. Announces Completion of High Resolution TEM Geophysical Survey at the Eagle Project and Provides Update on McCabe Mine Reopening StudiesToronto, Ontario--(Newsfile Corp. - November 12, 2026) - Arizona Eagle Mining Corp. (TSXV: AZEM) (OTCQB: AZEMF) (the "Company" or "Arizona Eagle") is pleased to announce the completion of a 708 line-kilometre airborne time-domain electromagnetic ("TEM") geophysical survey at its Eagle Project (the "Property") in the historic McCabe gold-silver district of Arizona. The survey was conducted by SkyTEM using a specially engineered system, referred to as the SkyTEM "Diamond", designed to provide exceptional near-surface resolution down to depths of 150 metres, making it ideal for delineating discrete structural features and identifying geophysical responses that may be associated with mineralization beneath shallow cover.
5 days ago · businesswire.com
Tempus to Present Six Abstracts Accepted at the 2026 Connective Tissue Oncology Society Annual MeetingCHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that six abstracts (including three oral presentations) will be presented at the 2026 Connective Tissue Oncology Society (CTOS) Annual Meeting taking place November 18–21 in Seoul. At this year's meeting, Tempus will present clinical research on rare mesenchymal tumors, highlighting how advances in molecular diagnosis and classification are unlocking new treatment options. This research leverages Tempus' expansive, de-ident.
6 days ago · prnewswire.com
Blood Cancer United Launches REALworld: AML to Accelerate New Treatments for Children with Blood CancerDare to Dream Project will build a real-world data set that can inform pediatric AML research and future clinical trials while helping families better understand their health information WASHINGTON, Nov. 10, 2026 /PRNewswire/ -- Blood Cancer United® today announced the launch of Dare to Dream REALworld: AML, a patient-centered initiative co-founded with Rally Foundation for Childhood Cancer Research. The initiative will engage current and former pediatric acute myeloid leukemia (AML) patients and their families to build real-world evidence that can inform research and future clinical trials, helping accelerate the development of new treatments.
7 days ago · prnewswire.com
SOTERIA Collaborates with Tempus to Advance Precision Oncology for U.S. Military and Veterans Battling CancerSAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- SOTERIA Precision Medicine Foundation , a non-profit 501(c)(3) organization, announced a collaboration with Tempus (NASDAQ: TEM) to deliver personalized, data-driven cancer treatment insights and advanced genomic sequencing to members of the U.S. active-duty and veteran military populations. The collaboration supports SOTERIA's Cancer Hunt™ initiative, delivering precision oncology patient navigation with Tempus' comprehensive genomic profiling and AI-enabled diagnostic platform to help identify targeted therapies and clinical trial opportunities for active service members and veterans.
9 days ago · seekingalpha.com
Tempus AI: Q3 Strengthens The Platform Thesis, But Cash Returns Still Need To Catch UpTempus is rated 'hold' as current valuation already prices in considerable future success. The platform's core strength lies in connecting diagnostic data with clinical outcomes, enhancing research value and recurring revenue potential. Q3 2026 showed strong revenue growth in both Diagnostics (+20%) and Data & Applications (+33%), with improving adjusted EBITDA but persistent GAAP losses.
13 days ago · seekingalpha.com
Tempus AI: An Inflection Point Has Arrived (Earnings Analysis)Tempus AI delivered robust Q3 results, with 23% YoY revenue growth and an inflection after four quarters of deceleration. Diagnostics volumes surged, notably MRD tests up 300% YoY, while Data & Applications revenue accelerated to 33% growth. Major partnerships with Bristol Myers Squibb, Moderna, and Merck validate TEM's strategic positioning in AI-driven medicine.
14 days ago · marketbeat.com
Tempus AI Surges on Earnings Beat, But Can the Rally Last?Tempus AI NASDAQ: TEM is among the more volatile AI-related stocks, trading in a wide range and testing upper limits several times since its IPO. Volatility stems from several factors, including the path to profitability, cash burn, and immense opportunity.
14 days ago · zacks.com
TEM Q3 Earnings Call Highlights Growth and 2027 Pricing UpsideTempus AI raises its 2026 revenue outlook as oncology demand, expanding data partnerships and reimbursement-driven pricing gains fuel growth prospects for 2027.
14 days ago · benzinga.com
Tempus AI Analysts Boost Their Forecasts Following Strong Q3 ResultsTempus AI Inc. (NASDAQ:TEM) on Monday posted upbeat results for the third quarter.
15 days ago · 247wallst.com
Do You Own Tempus AI Without Knowing It? Check These ETFs After Its Earnings SurgeTempus AI (NASDAQ:TEM | TEM Price Prediction) was trading higher this afternoon. It sat at $80.31, up 11.21% after the precision medicine company reported third-quarter results before the open.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove TEM